# Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial

Source: https://onco.cc/key-papers/paper-nct05246514-clin-lung-cancer-2026/  
OnCo record `paper-nct05246514-clin-lung-cancer-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the DESTINY-Lung05 trial registered as NCT05246514, in Clinical lung cancer (2026), chosen as the most cited paper whose own text cites the registry id.

## Summary

Introduction: Trastuzumab deruxtecan (T-DXd) was approved in China in October 2024 for previously treated human epidermal growth factor receptor 2 (HER2)-mutant (HER2m) unresectable/metastatic non-small cell lung cancer (NSCLC), based on DESTINY-Lung02 and DESTINY-Lung05 primary results. Here, we report the DESTINY-Lung05 final analysis.

Methods: DESTINY-Lung05 (NCT05246514), an open-label, single-arm, multicenter, phase 2 study, investigated T-DXd (5.4 mg/kg once every 3 weeks) in patients from China with HER2m (locally or centrally confirmed activating HER2 exon 19/20 mutation) metastatic NSCLC with disease progression on/after ≥ 1 prior anticancer therapy. The primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 by independent central review (ICR). Secondary endpoints included progression-free survival (PFS) by ICR, overall survival (OS), and safety.

Results: at November 4, 2024, 72 patients with HER2m NSCLC had received T-DXd 5.4 mg/kg; the median duration of follow-up was 20.2 months (range, 2-27). Confirmed ORR (ICR) was 56.9% (95% confidence interval [CI] 44.7-68.6). Median PFS (ICR) and OS were 9.9 months (95% CI 7.1-16.5) and 21.0 months (95% CI 17.5-not calculable), respectively. Grade ≥ 3 drug-related adverse events occurred in 40 (55.6%) patients. Adjudicated drug-related interstitial lung disease/pneumonitis events were observed in 9 (12.5%) patients (n = 8 grade 1/2; n = 1 grade 3).

Conclusions: With extended follow-up, T-DXd continued to demonstrate clinically meaningful and durable antitumor activity in patients from China with pretreated HER2m metastatic NSCLC, with no new safety signals. Results affirm the use of T-DXd as a treatment option in China for this patient population.

Indexed on Europe PMC as PubMed record 42480250 (DOI 10.1016/j.cllc.2026.06.003). Its abstract cites the registry id NCT05246514, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Clinical lung cancer
- Year: 2026
- DOI: 10.1016/j.cllc.2026.06.003
- Authors: Liu Y, Li D, Wu L, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT05246514 with the most citations, so it is the natural first reading for anyone following the DESTINY-Lung05 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Clin Lung Cancer 2026: https://doi.org/10.1016/j.cllc.2026.06.003
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42480250/
- Europe PMC: https://europepmc.org/article/MED/42480250
- ClinicalTrials.gov NCT05246514: https://clinicaltrials.gov/study/NCT05246514

## Connected records

- trials: [A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC](https://onco.cc/trials/nct05246514/)
- journals: [Clinical lung cancer](https://onco.cc/journals/clinical-lung-cancer/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct05246514-clin-lung-cancer-2026.json